Pediatric Hematology Oncology ...

Dr. Juan F. Rico

Claim this profile

Tampa General Hospital

Expert in Uterine Tumors
Expert in Cancer
29 reported clinical trials
80 drugs studied

About Juan F. Rico

Education:

  • Obtained a Medical Degree (MD) from the University of South Florida Morsani College of Medicine.
  • Completed a Residency in Internal Medicine at Tampa General Hospital.
  • Undertook a Fellowship in Pulmonary and Critical Care Medicine at Tampa General Hospital.

Experience:

  • Affiliated with Tampa General Hospital, specializing in Pulmonary Disease and Critical Care Medicine.

Area of expertise

1Uterine Tumors
Global Leader
Juan F. Rico has run 14 trials for Uterine Tumors. Some of their research focus areas include:
Stage I
Stage IV
Stage II
2Cancer
Global Leader
Juan F. Rico has run 11 trials for Cancer. Some of their research focus areas include:
Stage I
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.
Tampa General Hospital
Image of trial facility.
University Of South Florida

Clinical Trials Juan F. Rico is currently running

Image of trial facility.

Inotuzumab Ozogamicin

for Acute Lymphoblastic Leukemia

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria

More about Juan F. Rico

Clinical Trial Related7 years of experience running clinical trials · Led 29 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Juan F. Rico has experience with
  • Cyclophosphamide
  • Radiation Therapy
  • Etoposide
  • Vincristine Sulfate
  • Dexamethasone
  • Pegaspargase

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Juan F. Rico specialize in?
Juan F. Rico focuses on Uterine Tumors and Cancer. In particular, much of their work with Uterine Tumors has involved Stage I patients, or patients who are Stage IV.
Is Juan F. Rico currently recruiting for clinical trials?
Yes, Juan F. Rico is currently recruiting for 5 clinical trials in Tampa Florida. If you're interested in participating, you should apply.
Are there any treatments that Juan F. Rico has studied deeply?
Yes, Juan F. Rico has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Juan F. Rico?
Apply for one of the trials that Juan F. Rico is conducting.
What is the office address of Juan F. Rico?
The office of Juan F. Rico is located at: Tampa General Hospital, Tampa, Florida 33606 United States. This is the address for their practice at the Tampa General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security